SCHEMBL3473035

SCHEMBL3473035

O=C(Nc1ccc(C(F)(F)F)nc1)c1ccc(-c2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.55
DGAT2 Q96PD7 1/20 0.53
MAPT P10636 8/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
TP53 P04637 2/20 0.52
RXRA P19793 2/20 0.52
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 2/20 0.52
POLB P06746 1/20 0.51
THRB P10828 3/20 0.49
ORAI1 Q96D31 1/20 0.48
NR3C2 P08235 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472102 0.90 MAPT (0.61) CNR1DGAT2MAPTSMN1; SMN2TP53
SCHEMBL3472874 0.89 MAPT (0.56) CNR1DGAT2MAPTSMN1; SMN2TP53
SCHEMBL3471938 0.89 ORAI1 (0.60) CNR1MAPTSMN1; SMN2TP53RXRA
SCHEMBL3471277 0.89 MAPT (0.57) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3471324 0.89 MAPT (0.59) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472070 0.89 RXRA (0.57) CNR1DGAT2MAPTSMN1; SMN2TP53
SCHEMBL3475370 0.89 MAPT (0.54) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3474142 0.89 MAPT (0.59) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472028 0.88 NAMPT (0.51) CNR1MAPTSMN1; SMN2TP53RXRA
SCHEMBL3472857 0.88 MAPT (0.57) MAPTSMN1; SMN2TP53RXRANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 CNR1 49/4885DGAT2 499/4885MAPT 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.